Conference call for investors, analysts and the media on Friday, February 17 in connection with the company's Full Year Report

  Lund, Sweden - Alligator Bioscience AB (Nasdaq Stockholm; ATORX) announced today that it will host a teleconference in connection to publishing of the company's 2016 Full Year Report on Friday February 17 at 08.00 (CET).

Conference call for investors, analysts and the media
The report for 2016 will be presented by Alligator’s CEO Per Norlén and members of the management team of the company.

Time: Friday, February 17, 2017, at 10:00 (CET).

Telephone number of participants:
Europe: +44 (0) 2030089803

Sweden: +46 856642696
US +1 8558315946

The conference call will be available on the company's website after the completion of the conference:

About Alligator
Alligator is a research-based biotechnology company that develops innovative immune activating antibody drugs for tumor-directed immunotherapy. The Company is headquartered in Lund, Sweden, and had 35 employees per December 31, 2016. The Company is primarily active in the early stages of drug development, from the idea stage to clinical phase IIa studies, and Alligator’s product portfolio primarily consist of the product candidates ADC-1013, ATOR-1015 and ATOR-1016. In August 2015, ADC-1013 was out-licensed to Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for further development and commercialization. The company’s shares are listed on Nasdaq Stockholm under the ticker “ATORX”. For more information, visit

For further information, please contact:
Rein Piir, VP Investor Relations

Telephone: +46 708 537292

About Us

Alligator Bioscience discovers and develops innovative antibody based immunotherapies for the treatment of cancer. Alligator Drug Discovery and Development span early research phases with lead identification up to proof of concept phase I/II clinical studies in cancer patients. In the discovery of novel antibody based drugs, Alligator uses its proprietary technology platforms FIND® and ALLIGATOR-GOLD®. FIND® (Fragment INduced Diversity) is an antibody optimization technology based on single-stranded DNA allowing generation of antibodies with significant clinical benefits. ALLIGATOR-GOLD® is a synthetic svFv library containing several billion distinct fully human antibodies. Alligator Bioscience AB was founded in 2001 and is a privately held company, located at Medicon Village in Lund, Sweden.Alligators largest shareholders are the Copenhagen-based venture fund Sunstone Capital and DUBA AB, a fully-owned subsidiary of Investor AB, as well as some private individual investors.


Documents & Links